… dopamine, an important neurotransmitter in the brain. Here, we present a brief review of the
dopamine synthetic pathway, binding to the dopamine … on dopamine and the dopaminergic …

… -dopaminergic drugs have failed to show anti-dyskinetic efficacy, while some are still in
development. Non-dopaminergic targets … Drug repurposing continues to be a key strategy for non-…

… needs for the development of additional dopaminergic treatment options to improve current
DA-centered treatment. Most currently used dopaminergic drugs selectively activate D 2 -like …

… Dopamine replacement therapy with l-DOPA is the most efficacious symptomatic treatment
for Parkinson's disease… of dopaminergic degeneration and non-physiological reinstatement of …

… In this review, we summarized the development of preclinical and clinical studies of novel
drugs and the improvement of dopaminergic drugs to provide a prospect for PD treatment. …

… of life and primarily targets dopaminergic pathways. Dopamine acts through two families of
receptors, dopamine D1-like and dopamine D2-like; dopamine D3 receptors (D3R) belong to …

… This is in part because of the fact that the loss of a restricted population of dopamine … of
lost dopamine neurons should at least mimic that seen with standard dopaminergic drugs that …

… Parkinson Disease” practice guideline, 1 which contains recommendations regarding the use
of dopaminergic … the current evidence on initial dopaminergic treatment of motor symptoms …

… indicative of atypical parkinsonism (“red-flag symptoms”) and assesses the patient response
to levodopa (or potentially other dopaminergic medications) to confirm Parkinson disease. …

… this scenario is Parkinson’s disease (PD) … disease that involves a gradual loss of dopaminergic
neurons largely within nigrostriatal projections. Replacement therapy includes dopamine …